Saturday 17 October 2026
Export FTH’s income statement to Excel — free account
Faeth Therapeutics, Inc.
In the quarter to June 2026, EPS grew 27.4% and free cash flow fell 174.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
18.79
1.81
−8.79%
Follow FTH
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 94.00 | 26.00 | 10.20 | 7.68 | 5.00 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 530.00 | 123.40 | 38.52 | 38.80 | 18.35 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 32 | 56 | 28 | 27 | 15 | 23 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | (13) | (17) | (20) | (37) | (49) | (34) | (30) | (21) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (13) | (17) | (20) | (37) | (49) | (34) | (30) | (21) | |||||
| Depreciation | — | — | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (0.57) | (911.37) | (250.60) | (26.60) | (31.60) | (24.40) | (24.00) | (16.72) | |||||
| Cash flow | — | — | (0.35) | (465.82) | (219.66) | (21.84) | (25.42) | (22.91) | (19.64) | (16.22) | |||||
| Capex | — | — | 0.00 | (2.88) | (14.96) | (1.23) | (0.20) | (0.01) | (0.12) | 0.19 | |||||
| Free cash flow | — | — | (0.35) | (468.70) | (234.63) | (23.07) | (25.62) | (22.92) | (19.76) | (16.03) | |||||
| Book value | — | — | (0.20) | (3,731.63) | (700.29) | 105.74 | 67.36 | 46.43 | 30.56 | 14.74 | |||||
| Shares, m | — | — | 29 | 0 | 0 | 1 | 2 | 1 | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (10) | (9) | (18) | (30) | (39) | (32) | (25) | (20) | ||||
| Capex | — | — | 0 | 0 | (1) | (2) | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | (10) | (9) | (19) | (32) | (39) | (32) | (25) | (20) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | (1) | (21) | 15 | 144 | 100 | 62 | 36 | 17 | ||||
| Total debt | — | — | 5 | 16 | 1 | 2 | 2 | 1 | 0 | — | |||||
| Net debt | — | — | 4 | 16 | (16) | (146) | (106) | (65) | (41) | (21) | |||||
| Shareholders’ equity | — | — | (6) | (69) | (56) | 147 | 103 | 65 | 38 | 19 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (1,820.86) | (1,339.68) | (178.44) | (42.13) | (35.78) | (35.38) | (50.37) | (61.78) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (4,138.91) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | 27.58 | 33.64 | 32.30 | (81.70) | (38.88) | (40.52) | (58.40) | (74.01) | |||||
Negative figures in brackets.
Charts ten years each
Faeth Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VALN Valneva SE Sponsored ADR | $560.4M | 59.7× | 19.4× | −17.29% (below 0%: shrinking) | n/m | −56.05% (below 0%: shrinking) | 15.29% | (76.67%) | Compare |
| STTK Shattuck Labs, Inc. | $555.0M | — (loss-making) | — (loss-making) | −10.31% (below 0%: shrinking) | n/m | +1.01% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VECT VectivBio Holding AG | $545.5M | — (loss-making) | — (loss-making) | — | n/m | — | 91.93% | 0.00% | Compare |
| PBYI Puma Biotechnology, Inc. | $543.0M | 18.2× | 24.2× | +7.75% (above 0%: growing) | +33.33% (above 0%: growing) | −88.45% (below 0%: shrinking) | 77.92% | 13.42% | Compare |
| DRUG Bright Minds Biosciences Inc. | $534.7M | — (loss-making) | — | — | n/m | −124.63% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FTH Faeth Therapeutics, Inc. | $532.3M | — (loss-making) | — | — | n/m | −174.24% (below 0%: shrinking) | 0.00% | 0.00% | |
| CTMX CytomX Therapeutics, Inc. | $525.1M | — (loss-making) | — (loss-making) | −92.40% (below 0%: shrinking) | n/m | −14.50% (below 0%: shrinking) | 100.00% | (1,677.08%) | Compare |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR | $524.8M | — (loss-making) | — (loss-making) | −7.53% (below 0%: shrinking) | n/m | −31.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ACRS Aclaris Therapeutics, Inc. | $513.7M | — (loss-making) | — (loss-making) | −8.33% (below 0%: shrinking) | n/m | −98.77% (below 0%: shrinking) | 10.80% | (1,487.91%) | Compare |
| Median of peers | $538.9M | — | — | −9.32% | — | −56.05% | 46.61% | 0.00% |
Faeth Therapeutics, Inc. (FTH) key facts
- Faeth Therapeutics, Inc. (FTH) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, FTH traded at $18.79, a market capitalization of $532.3 million.
- Return on equity was −74.0% and debt-to-equity 0.00.